These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3411456)

  • 1. Pharmacodynamics of chlorzoxazone in rats.
    Kaneko I; Fukumori Y; Fukuda T; Takeuchi Y
    J Pharm Sci; 1988 May; 77(5):383-6. PubMed ID: 3411456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of alpha-chloralose on muscle relaxant effect of chlorzoxazone in rats and pharmacodynamic analysis.
    Kaneko I; Fukumori Y; Fukuda T; Takeuchi Y
    J Pharmacobiodyn; 1989 Aug; 12(8):441-7. PubMed ID: 2614638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of zoxazolamine and chlorzoxazone in rats.
    Yasuhara M; Levy G
    Pharm Res; 1988 Jul; 5(7):401-7. PubMed ID: 3247308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of disposition kinetics to pharmacological effect of intravenous administration of chlorzoxazone in rats.
    Kaneko I; Fukumori Y; Fukuda T; Takeuchi Y
    J Pharmacobiodyn; 1990 Jun; 13(6):367-73. PubMed ID: 2231268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of alpha-chloralose on disposition and pharmacological action of orally administered chlorzoxazone in rats.
    Kaneko I; Takeuchi Y; Fukumori Y; Fukuda T
    J Pharmacobiodyn; 1991 Aug; 14(8):429-34. PubMed ID: 1774620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Behavioral and EEG effects of coixol (6-methoxybenzoxazolone), one of the components in Coix Lachryma-Jobi L. var. ma-yuen Stapf].
    Gomita Y; Ichimaru Y; Moriyama M; Fukamachi K; Uchikado A; Araki Y; Fukuda T; Koyama T
    Nihon Yakurigaku Zasshi; 1981 Mar; 77(3):245-59. PubMed ID: 7052357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of drug action in disease states. XXVII. Effect of experimental renal failure on the pharmacodynamics of zoxazolamine and chlorzoxazone.
    Yasuhara M; Levy G
    J Pharmacol Exp Ther; 1988 Jul; 246(1):165-9. PubMed ID: 3260625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulatory effects of chlorzoxazone, a centrally acting muscle relaxant, on large conductance calcium-activated potassium channels in pituitary GH3 cells.
    Liu YC; Lo YK; Wu SN
    Brain Res; 2003 Jan; 959(1):86-97. PubMed ID: 12480161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electromyographic tests for the evaluation of effects of myotonolytic drugs in muscular reflexogenic hyperreflexive states.
    Bonne A; Heymans W; Rosselle N
    Electromyography; 1970; 10(3):219-25. PubMed ID: 5509968
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of glucose supplementation on the pharmacokinetics of intravenous chlorzoxazone in rats with water deprivation for 72 h.
    Kim YC; Lee I; Kim SG; Ko SH; Lee MG; Kim SH
    Life Sci; 2006 Nov; 79(23):2179-86. PubMed ID: 16914164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chlorzoxazone inhibits contraction of rat thoracic aorta.
    Dong DL; Luan Y; Feng TM; Fan CL; Yue P; Sun ZJ; Gu RM; Yang BF
    Eur J Pharmacol; 2006 Sep; 545(2-3):161-6. PubMed ID: 16859676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhibition of a neutral protease from human leukocyte granules by antirheumatic agents].
    Menninger H; Kruze D; Fehr K; Böni A
    Verh Dtsch Ges Rheumatol; 1978; 5():204-7. PubMed ID: 706666
    [No Abstract]   [Full Text] [Related]  

  • 13. Chlorzoxazone hepatotoxic reactions. An analysis of 21 identified or presumed cases.
    Powers BJ; Cattau EL; Zimmerman HJ
    Arch Intern Med; 1986 Jun; 146(6):1183-6. PubMed ID: 3521519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of a new centrally acting muscle relaxant (RJ-64).
    Leszkovszky GP; Tardos L
    Arzneimittelforschung; 1970 Nov; 20(11):1778-83. PubMed ID: 4321623
    [No Abstract]   [Full Text] [Related]  

  • 15. A pharmaceutical study on chlorzoxazone orodispersible tablets: formulation, in-vitro and in-vivo evaluation.
    Moqbel HA; ElMeshad AN; El-Nabarawi MA
    Drug Deliv; 2016 Oct; 23(8):2998-3007. PubMed ID: 26828616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of recombinant small-conductance Ca(2+)-activated K(+) channels by the muscle relaxant chlorzoxazone and structurally related compounds.
    Cao Y; Dreixler JC; Roizen JD; Roberts MT; Houamed KM
    J Pharmacol Exp Ther; 2001 Mar; 296(3):683-9. PubMed ID: 11181893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
    Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
    Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1.
    Blakey GE; Lockton JA; Perrett J; Norwood P; Russell M; Aherne Z; Plume J
    Br J Clin Pharmacol; 2004 Feb; 57(2):162-9. PubMed ID: 14748815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological studies of the new centrally acting muscle relaxant 4'-ethyl-2-methyl-3-pyrrolidinopropiophenone hydrochloride.
    Morikawa K; Oshita M; Yamazaki M; Ohara N; Mizutani F; Kato H; Ito Y; Kontani H; Koshiura R
    Arzneimittelforschung; 1987 Mar; 37(3):331-6. PubMed ID: 3593447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of Cl(-) secretion by chlorzoxazone.
    Singh AK; Devor DC; Gerlach AC; Gondor M; Pilewski JM; Bridges RJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):778-87. PubMed ID: 10640318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.